We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
Cap. Flow
+$327M
Cap. Flow %
24.74%
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$86.8M
2
RAD
Rite Aid Corporation
RAD
+$67.2M
3
PEN icon
Penumbra
PEN
+$63.2M
4
SAGE
Sage Therapeutics
SAGE
+$52.5M
5
INCY icon
Incyte
INCY
+$50.3M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$85.4M
2
AGN
Allergan plc
AGN
+$41.5M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$36.3M
4
HCA icon
HCA Healthcare
HCA
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 9.13%
3 Communication Services 1.09%
4 Industrials 1%
5 Technology 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PPH icon
51
VanEck Pharmaceutical ETF
PPH
$993M
$409K 0.03%
6,500
– –
SRRA
52
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$377K 0.03%
+460
New +$519K
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$311K 0.02%
3,211
-9,117
-74% -$1.09M
JAZZ icon
54
Jazz Pharmaceuticals
JAZZ
$15.9B
$235K 0.02%
1,769
-149,097
-99% -$25.7M
CERN
55
DELISTED
Cerner Corp
CERN
$214K 0.02%
+3,563
New +$233K
LAB icon
56
Standard BioTools
LAB
$252M
$199K 0.02%
24,583
-323,654
-93% -$5.09M
NXTM
57
DELISTED
NxStage Medical Inc.
NXTM
$186K 0.01%
+11,800
New +$189K
ABBV icon
58
AbbVie
ABBV
$451B
– –
-510,010
Closed -$34.3M
BHC icon
59
Bausch Health
BHC
$2.36B
– –
-384,506
Closed -$85.4M
BIIB icon
60
Biogen
BIIB
$32.3B
– –
-79,118
Closed -$32M
CI icon
61
Cigna
CI
$73.7B
– –
-198,700
Closed -$32.2M
DVA icon
62
DaVita
DVA
$11.5B
– –
-140,191
Closed -$11.1M
HCA icon
63
HCA Healthcare
HCA
$90.5B
– –
-390,000
Closed -$35.4M
IHF icon
64
iShares US Healthcare Providers ETF
IHF
$1.23B
– –
-42,995
Closed -$1.23M
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-67,425
Closed -$6.9M
UHS icon
66
Universal Health Services
UHS
$10.1B
– –
-175,965
Closed -$25M
BLCM
67
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-23,812
Closed -$5.07M
SIOX
68
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-18,750
Closed -$3.06M
FLXN
69
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-142,483
Closed -$3.12M
GWPH
70
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-146,027
Closed -$17.9M
AGN
71
DELISTED
Allergan plc
AGN
– –
-136,818
Closed -$41.5M
CIVI
72
DELISTED
Civitas Solutions, Inc.
CIVI
– –
-657,693
Closed -$14M
AET
73
DELISTED
Aetna Inc
AET
– –
-264,075
Closed -$33.7M
ALR
74
DELISTED
Alere Inc
ALR
– –
-461,170
Closed -$24.3M
KYTH
75
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-482,556
Closed -$36.3M
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2015 Portfolio in Review

As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.

  • Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
  • Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
  • Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
  • Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
  • Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
  • Redmile Group opened 22 new positions and closed 19 in Q3 2015.
  • Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.